Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 112,548

Document Document Title
WO/2016/057658A8
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/057713A1
Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modul...  
WO/2016/055517A1
The present invention relates to a compound for use in the treatment and/or prevention of diseases or disorders wherein an inhibition of protein prenylation is required, which is alternatively chosen, among formulae (I) and (II), wherein...  
WO/2016/055482A1
The present invention relates to isoindoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors pla...  
WO/2016/056520A1
 Provided are a feed for aquatic animals and a growth promoter for aquatic animals that result in the healthy growth of fish and impart strong recovery capabilities thereto, even when water temperatures are substantially higher than no...  
WO/2016/055496A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2016/055858A1
The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's ...  
WO/2016/055160A3
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encodi...  
WO/2016/057658A1
Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular d...  
WO/2016/051024A1
The present invention relates to pounds of general formula (I) and pharmaceutically acceptable salts thereof; wherein R1 - R11, L, Z, Y, and Z are as defined in the claims. The invention also relates to said compounds for use as a medica...  
WO/2016/052656A1
An autophagy inducing agent that comprises at least one member selected from a compound represented by structural formula (A), a compound represented by structural formula (B), and a compound represented by structural formula (C).  
WO/2016/051155A1
A compound of the general formula A or a or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is selected from the group consisting of: C1-C12-alkyl, C3-C12-cycloalkyl, C6- C10-aryl, and C5-C7-heteroaryl; each optionally...  
WO/2016/051420A1
The invention relates to the compounds of formula II or their pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The invention further relates to pharmaceutical compositions...  
WO/2016/053947A1
Disclosed is a crystalline polymorph 1-(1-methyl-1H-pyrazol-4-yl)-N-((1R,5S,7S)- 9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-ca rboxamide, Form G, and processes for making the same  
WO/2016/053794A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2016/049884A1
Provided are a conotoxin polypeptide κ-CPTx-bt105, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 16 amino acids, has a molecular weight of 1626.62 daltons, and has the full sequence ...  
WO/2016/051196A1
The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)- prolina...  
WO/2016/049864A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt101, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 18 amino acids, has a molecular weight of 1872.72 daltons, ...  
WO/2016/050975A1
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders...  
WO/2016/051194A1
The present invention is directed to the treatment of erythromelalgiacomprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4- {[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamideor a pharmaceutically...  
WO/2016/049700A1
The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.  
WO/2016/054432A1
The present invention is directed to copolypeptide hydrogels (DCH) containing non-ionic hydrophilic residues (DCHEO ), incorporation of thermoresponsive elements into DCHEO, to generate thermoresponsive DCH (DCHT), and hydrogels that inc...  
WO/2016/049881A1
Provided are a conotoxin polypeptide κ-CPTx-bt104, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 11 amino acids, has a molecular weight of 1313.47 daltons, and has the full sequence ...  
WO/2016/049873A1
Provided are a conotoxin polypeptide κ-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide consists of 29 amino acids, has a molecular weight of 3141.43 daltons, and has the full sequence ...  
WO/2016/052617A1
The present invention addresses the problem of providing a nalfurafine-containing preparation for topical application that has high drug stability in the preparation and excellent drug transfer properties from the preparation to a living...  
WO/2016/050160A1
Provided is a paliperidone oral controlled-release tablet, comprising: a single-layer tablet core containing paliperidone, a first coating layer and a second coating layer coating the single-layer tablet core to control release of medica...  
WO/2016/054475A1
The instant disclosure features, among other things, compositions and methods for treating an autism spectrum disorder in a human. The compositions comprise an effective amount of: (1) an isothiocyanate (e.g., sulforaphane or a derivativ...  
WO/2016/051195A1
The present invention is directed to the treatment of small fibre neuropathy comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmace...  
WO/2016/050203A1
A use of a casein kinase 2 inhibitor in preparing a pharmaceutical composition for enhancing the expression of type I interferon and/or a type I interferon-induced gene or a protein thereof; and/or in preparing a pharmaceutical compositi...  
WO/2016/051181A1
This invention relates to novel compounds of formula (I) wherein wherein Ά' is a 5 or 6 membered aryl or heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1R81)n- (wherein n ...  
WO/2016/052522A1
The purpose of the present invention is to provide a method for preventing the degeneration of ropinirole in a ropinirole-containing preparation for percutaneous administration. A preparation for percutaneous administration, said prepara...  
WO/2016/053946A1
Provided are methods for reducing the progression of cognitive decline in a post¬ menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.  
WO/2016/049869A1
Disclosed are a conotoxin polypeptide κ-CPTx-bt102, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 15 amino acids, has a molecular weight of 1660.61 daltons, ...  
WO/2016/053767A1
The present invention provides four crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pa...  
WO/2016/051799A1
Provided is a tau aggregation inhibitor which is capable of sufficiently suppressing tau aggregation in cells. The present invention is a compound represented by formula (I) or a salt thereof. This compound is used for at least one appli...  
WO/2016/047638A1
Provided is: a cyclic peptide derivative which is derived from Paecilomyces tenuipes having an astrocyte proliferative activity; or a salt thereof.  
WO/2016/047924A3
The present invention relates to a fluorescent-labeled novel dieckol derivative.  
WO/2016/046638A3
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-meth ylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vo...  
WO/2016/046162A1
The invention relates to pharmaceutical compositions comprising proline or proline derivatives and their use in the treatment of dementia, Alzheimer's and neurodegenerative diseases.  
WO/2016/044929A1
The present relates to the use of miRNA-132/212 mimics or activators comprising a doubled stranded ribonucleic acid molecule comprising a seed region sequence of miRNA-132 or miRNA-212, a spacer, a stabilizing sequence, and a carrier for...  
WO/2016/047678A1
 The present invention provides an agent for the prevention or treatment of autoimmune disease, inflammatory disease (especially inflammatory skin disease) (for example, systemic lupus erythematosus, inflammatory bowel disease, psorias...  
WO/2016/046374A1
The invention relates to methylphenidate or to a physiologically acceptable salt thereof for use in the treatment of anorexia nervosa. The invention also relates to a corresponding pharmaceutical composition.  
WO/2016/048058A1
The present invention is characterized in that racemic or optically active D- or L-α―glycerophosphoryl choline solids are prepared from liquid type racemic or optically active D- or L-α―glycerophosphoryl choline using an organic so...  
WO/2016/046817A1
A composition-of-matter is provided. The present composition includes dietary supplements capable of reducing or reversing the negative effects of alcohol on motor and cognition, dietary supplements having anti-gastroparesis, antiemetic,...  
WO/2016/049355A1
Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed...  
WO/2016/046835A1
The invention relates to the compounds of formula I and formula laor its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of f...  
WO/2016/046669A3
The invention relates to the compounds and compositions of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions...  
WO/2016/046673A1
The compositions and compounds of formula I which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutic...  
WO/2016/047924A2
The present invention relates to a fluorescent-labeled novel dieckol derivative.  
WO/2016/046404A1
The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I) and pharmaceutical compositions containing them. Moreover, the compounds of formula (I) and the compositions containing ...  

Matches 501 - 550 out of 112,548